Good MorningEquity markets retreat on Thursday after another bad economic report, and earnings from Netflix and Tesla disappointed the market. On the economic front, the Index of Leading Indicators was negative for the 15th consecutive month and worse than expected at -0.7%. That was compounded by a negative reading of the Philly Fed Survey and earnings reports from Netflix and Tesla. Both companies failed to inspire market rallies and saw their shares fall by high-single to low-double-digits, and deeper declines could be coming.
The S&P 500 fell nearly a full percent at the session's low to confirm resistance at this week's high. The move could lead to a larger decline, given the outlook for earnings has taken a hit. If the market can't regain its footing on Friday, selling could gain momentum on Monday ahead of the FOMC meeting. The FOMC is expected to hike rates by another 25 basis points, putting more pressure on the economy. In this scenario, more banks will fail, and the economy will teeter closer to the recession lurking around the corner for the last 12 months. Featured: 100% overnight gains? (Ad) 
|
Industrials | |
Airline giant American Airlines Group (NASDAQ: AAL) reported second-quarter 2023 earnings results. The stock is trading down 6% in early trading as investors digest the report, perhaps providing an opportunity for patient value investors to buy in.
Investing in momentum is one thing; investing b... Read the Full Story |
|
From Our Partners | | Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold.
Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program.
With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district. | | See why this overlooked gold explorer could be entering its most important stage |
|
Consumer Discretionary | | As dubious as the signals within the housing market, stocks like D.R. Horton (NYSE: DHI) have been rallying to new highs. The rally is driven by outperformance in the face of rising rates and falling mortgage demand, and it may continue. The Q3 report is more of the same strength, but there is a cav... Read the Full Story |
|
Industrials | | The market rally is starting to extend beyond the “Magnificent 7” tech stocks. Yet many analysts and economists still believe investors may be in for a nasty pullback before the year ends.
Market timing is difficult for the best of investors. But there’s still a solid strategy t... Read the Full Story |
|
From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
|
Healthcare | |
After three years of waiting, Johnson & Johnson (NYSE: JNJ) shares have returned to trend, a monumental event for the market which presents a potential buying opportunity for income investors.
Not only is Johnson & Johnson's business sound but results from competitors like Abbott Laborato... Read the Full Story |
|
Technology | |
As the COVID-19 peak effect periods expired in 2021 and 2022, the chip industry's severe shortages caused delays in other pockets of the economy, such as new vehicles and consumer electronic products. Almost everything relying on chips saw delayed orders and increased lead times.
As the environme... Read the Full Story |
|
From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
|
Healthcare | |
Abbott Laboratories (NYSE: ABT) is a tale of two stories. The first is its recovery from the COVID-19 boost and bubble. The second is the underlying core business, which is as strong as ever.
The company is "shrinking" due to the COVID-19-related testing and sales decline. The organic business i... Read the Full Story |
|
Consumer Discretionary | |
Homebuilders traded lower as a group on July 19, ending the session down 0.20% after the National Association of Homebuilders reported that June housing starts fell more than expected.
As a whole, homebuilder stocks were down for the session. The SPDR S&P Homebuilders ETF (NYSEARCA: XHB) and... Read the Full Story |
|
Industrials | |
Shares of Panamanian airline Copa Holdings S.A. (NYSE: CPA) are flying after two analysts boosted their price targets in July. The stock is in a buy zone after rebounding from a shallow pullback near its 21-day moving average.
Like many airlines in the U.S. and worldwide, Copa benefited from a s... Read the Full Story |
|
Technology | |
One of the hottest topics right now is artificial intelligence (AI), and any stock that finds itself linked has experienced a wave of buying momentum. Since NVIDIA Corp's (NASDAQ: NVDA) last-quarter earnings, semiconductor stocks have been intrinsically linked to the AI story. As a result, semicon... Read the Full Story |
|
Consumer Discretionary | | Tesla (NASDAQ: TSLA) shares have been rocketing higher all year, and by rights, they should continue to do so. The Q2 results are a testament to Elon Musk’s dedication and leadership abilities proving that his strategies work. The company ramped production by a mind-boggling rate compared to l... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
